Features | Partner Sites | Information | LinkXpress
Sign In
Primedic
CARDIOSTIM
Ampronix

Vascular Closure Device Preserves the Femoral Artery

By HospiMedica International staff writers
Posted on 28 Feb 2013
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
An innovative extravascular device facilitates entry site closure in patients undergoing percutaneous procedures through the femoral artery.

The Vascade Vascular Closure System (VCS) utilizes a unique delivery system based on a proprietary collapsible disc technology made of a biconvex low-profile nitinol, which provides temporary hemostasis during the procedure, eliminating the need for an intravascular component. Secure and rapid hemostasis is achieved by the deployment of a thrombogenic, resorbable collagen hemostatic coating patch, which accelerates coagulation at the arteriotomy site in the femoral artery by expanding approximately 13 times in volume, thus ensuring that the residual tissue tract is sufficiently filled and provides mechanical hemostasis.

The VCS is indicated for femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a procedural sheath. The simple-to-use technique avoids the need for sheath exchange or added complexity, enabling deployment in as little as 30 seconds. The Vascade VCS is a product of Cardiva Medical (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Vascade is a new generation of extravascular closure technology that offers significant advantages over conventional closure devices and manual compression,” said Frank Zidar, MD, of the Heart Hospital of Austin (TX, USA). “I am excited to be able to provide Vascade to my patients and to integrate it into my practice.”

The safety and effectiveness of Vascade VCS was evaluated in 420 patients across 21 clinical sites (up to 30 days post diagnostic or interventional procedures), that showed that the system is more effective than manual compression for mean time for hemostasis (TTH) and mean time to ambulation (TTA), and with fewer complications.

Related Links:

Cardiva Medical



Channels

Women's Health

view channel

Fetal ECG Readings Offer No Advantage During Labor

A new technology that provides electrocardiogram (ECG) readings of the fetus heart during the birth process offers no advantages over conventional monitoring, according to a new study. Researchers at the US National Institute of Child Health and Human Development (NICHD; Bethesda, MD, USA), the University of Texas Medical... Read more

Hospital News

view channel
Image: The future site of the Springdale ACH campus on I-49, across from Arvest Ballpark (Photo courtesy of ACH).

Arkansas Children's Hospital to Develop Springdale Facility

Arkansas Children's Hospital (ACH; Little Rock, USA) has unveiled plans to develop a new hospital campus in Springdale, which will involve an investment of USD 184 million during the next five years.... Read more

Business

view channel
Image: The Centor 1-Clic vial (Photo courtesy of Centor).

Gerresheimer Buys Plastic Vials Maker Centor

Advanced healthcare glass and plastic products manufacturer Gerresheimer (Düsseldorf, Germany) has agreed to purchase plastic vial maker Centor (Perrysburg, OH, USA) for USD 725 million in cash.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.